Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Sep 14 - Sep 19
Q: When should B12.COM Injection be administered
Food and Drug Administration (FDA), BPC-157 is not approved for any human therapeutic indication and has been restricted from use in compounding pharmacies due to a lack of safety data
About the Author Maryke Louw is a chartered physiotherapist with more than 20 years' experience and a Masters Degree in Sports Injury Management
Dairy is also a good source of B12
How it helps disc herniation specifically: Upregulates tendon-related growth factors BPC-157 activates the Egr-1 transcription factor, which drives collagen synthesis in fibrous tissue including the annulus fibrosus Promotes angiogenesis increases VEGF expression, improving blood supply to the avascular disc environment Neuroprotective effects multiple rodent studies show BPC-157 accelerates peripheral nerve regeneration and protects against nerve compression injury Systemic anti-inflammatory suppresses pro-inflammatory cytokine cascades without the immunosuppressive side effects of steroids Protocol: Dose: 250500mcg/day subcutaneous injection Injection site: Lower abdomen or closest accessible subQ site to the injury (though systemic distribution means proximity matters less than for localized joint issues) Duration: 68 weeks loading phase, reassess at week 8 Most people notice reduced nerve pain and improved mobility within 24 weeks
As compounded semaglutide is manufactured in compounding pharmacies, its quality varies among pharmacies, depending on the standard of the compounding pharmacy
US$ 26.53
US$ 27.24
US$ 20.30
US$ 27.70
US$ 26.16